Comparative Analysis of COVID-19 Vaccines


  •   Hassan Naji


SARS-CoV-2 is the cause of the recent outbreak of COVID-19. This outbreak has resulted in many infected individuals worldwide. The unavailability of a specific antiviral treatment caused many individuals to lose their lives due to COVID-19. The rising number of deaths and rapidly spreading infection demand the development of an effective vaccine against the virus. Many researchers and companies across the globe have started attempts to create effective vaccine that can provide quick and long-lasting protection against SARS-CoV-2. These vaccines employ different forms of constituents that ultimately stimulate the immune response to produce neutralizing antibodies in an individual. Among these vaccines are AZD1222, BNT162b2, and mRNA-1273.

Keywords: 2019-nCoV, SARS-CoV-2, Coronavirus, Novel Coronavirus, AZD1222, BNT162b2, mRNA-1273, Pfizer, Moderna, Oxford University, Spike (S) glycoproteins, ACE2 Receptors


Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases.

World Health Organization (WHO, 2020). Weekly Epidemiological Update – 29 December 2020. Retrieved from

Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., King, N. P. (2020). Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell.

Hassan, A. O., Kafai, N. M., Dmitriev, I. P., Fox, J. M., Smith, B. K., Harvey, I. B., Diamond, M. S. (2020). A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell.

Kemp, A. (2020, November 23). AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. Retrieved December 13, 2020, from

Pfizer. (2020, November 18). Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. Retrieved from

Johnson, C. (2020, December 15). FDA review clears path for second coronavirus vaccine, this one developed by Moderna. Retrieved December 16, 2020, from

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Beigel, J. H. (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine.

Pfizer. (2020, November 20). Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine. Retrieved from


Download data is not yet available.


How to Cite
Naji, H. (2021). Comparative Analysis of COVID-19 Vaccines. European Journal of Medical and Health Sciences, 3(1), 118-120.